Tradename
Decapeptyl
Generic Name
Triptorelin acetate
Category
Genitourinary System
Form
Injection
Composition
Each disposable syringe with 1 ml injectable solution contains:
Triptorelin acetate..............0.1 and 0.5 mg
Description
Properties/Actions
Decapeptyl is a synthetic analogue of gonadorelin (GnRH). As a result of the substitution of the 6th amino acid residue in the native molecule, the agnostic effect is more pronounced and the plasma half-life prolonged.
Daily injection of Decapeptyl initially results in a stimulation of the pituitary release of LH and FSH. After prolonged stimulation the pituitary becomes refractory, the gonadotropin release declines, resulting in a decrease of the sex steroids (testosterone or estrogen) to castrate levels. The effects are reversible.
Indications
Decapeptyl is indicated in situations where lowering of sex steroid serum levels to castrate levels is desired. For example:
Men
Therapy: Symptomatic treatment of an advanced hormone-dependent prostate carcinoma.
Diagnostic agent: To clarify through differential diagnosis the hormonal dependence of a prostate carcinoma.
Women
Endometriosis, Uterine Myoma, IVF
Contraindications
Drug Interactions
Side Effects/Adverse Effects
The pharmacological side effects owing to the suppression of hormone production include:
In Men
Hot flushes, impotence and loss of libido, gynceomastia
In Women
Hot flushes, vaginal dryness and/or dyspareunia, spotting and as a result of the decrease of estrogen levels to post-menopausal values, slight trabceular bone loss may occur. However, this is recovered completely within 6-9 months after treatment has been discontinued.

Less frequent side effects reported include:
In rare cases allergic reactions (fever, itching, exanthema, anaphylaxia), headache, tiredness and sleep disturbances. In general, the side effects are mild and disappear after treatment has been stopped.
Pregnancy & Lactation
In animal tests, no teratogenic effects have been detected. In humans, there is insufficient experience.
There are insufficient data relating to the use of Decapeptyl during lactation.
Dosage & Administration
Usual Dose:
  • 0.5 mg s.c. daily for 7 days
  • Followed by 0.1 mg daily as maintenace dose
IVF:
  • 7 to 10 days with 0.5 mg s.c.
  • Followed by 0.1 mg s.c. daily
Overdosage
Warnings
Monitoring of the therapy should be performed according to the sex steroid serum levels.
Assisted Reproduction
To prevent hyperstimulation, careful monitoring of follicular growth and luteal phase especially in patients with polycystic ovaries.
Men
The initial transient increase of serum testosterone has, in a few patients, been associated with a temporary aggravation of seconday symptoms of the disease, e.g. urinary obstructions, skeletal pain due to metastasis. Close monitoring durign the first weeks of treatment should, in these cases, be carried out. The temporary increase of serum testosterone levels can be avoided by treatment with an anti-androgen during the first treatment period.
Women
Prior to treatmnet, non-pregnancy should be confirmed. During the first month of treatment, patients should use non-hormonal contraceptive. Women should not use preparations containing estrogens during the Decapeptyl therapy. During treatment of uterine myoma, uterus and myoma size should be measured regularly by means of, for example, ultrasonography. Unproportionally rapid reduction of uterus volume in comparison with myoma tissue has, in few cases, caused bleeding and sepsis.
Notes
Storage
The disposable syringes should be stored in the package, protected from light.
Packaging
Decapeptyl 0.1 mg: Box of 7 or 28 disposable syringes of 1 ml solution each.
Decapeptyl 0.5 mg: Box of 7 disposable syringes of 1 ml solution each.
Manufacturer
Ferring Pharmaceuticals
Date Added/Updated
29th November 2011 1:44pm

Miscellaneous

Share This!

Respected Sites

drugs.com

rxlist.com

rxwiki.com

Need Help?

on-call support